This case study—developed by FDA, Conformia, Inc., and a working group of industry experts—is a milestone document on how to apply a science- and risk-based approach to product and process development for acetriptan ("ACE") 274 tablets, and how to document it in a knowledge-based report.

For the full 92-page report, click here.